# Nortech Systems Inc: Form 10-Q for the period ended Sep 30, 2018

- Company: [Nortech Systems Inc](/companies/nsys.md) (CIK 722313)
- Form: 10-Q
- Filed: 2018-11-14
- Accepted by EDGAR: Nov 14, 2018, 16:20 ET
- Period: 2018-09-30
- Accession: 0001104659-18-068455
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/722313/000110465918068455/a18-19024_110q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/722313/000110465918068455/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2018-07-01 to 2018-09-30 | $29.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2018-01-01 to 2018-09-30 | $84.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2018-07-01 to 2018-09-30 | $26.2m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2018-01-01 to 2018-09-30 | $74.3m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2018-07-01 to 2018-09-30 | $3.4m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2018-01-01 to 2018-09-30 | $10.2m | us-gaap:GrossProfit |
| Operating income | 3 months, 2018-07-01 to 2018-09-30 | $649.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2018-01-01 to 2018-09-30 | $1.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2018-07-01 to 2018-09-30 | $170.0k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2018-01-01 to 2018-09-30 | $551.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2018-07-01 to 2018-09-30 | $115.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2018-01-01 to 2018-09-30 | $350.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2018-07-01 to 2018-09-30 | $364.0k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2018-01-01 to 2018-09-30 | $362.0k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2018-07-01 to 2018-09-30 | $0.14 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2018-01-01 to 2018-09-30 | $0.13 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2018-07-01 to 2018-09-30 | $0.14 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2018-01-01 to 2018-09-30 | $0.13 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2018-07-01 to 2018-09-30 | 2,682,091 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2018-01-01 to 2018-09-30 | 2,702,503 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2018-01-01 to 2018-09-30 | $2.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2018-01-01 to 2018-09-30 | $999.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months, 2018-01-01 to 2018-09-30 | $229.0k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2018-09-30 | $397.0k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2018-09-30 | $43.3m | us-gaap:AssetsCurrent |
| Total assets | at 2018-09-30 | $57.4m | us-gaap:Assets |
| Current liabilities | at 2018-09-30 | $23.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2018-09-30 | $36.1m | us-gaap:Liabilities |
| Long-term debt | at 2018-09-30 | $3.7m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2018-09-30 | $871.0k | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2018-09-30 | $21.3m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 19,443 characters.

### Overview

We are a Maple Grove, Minnesota based full-service electronics manufacturing services (“EMS”) contract manufacturer of wire and cable assemblies, printed circuit board assemblies, higher-level assemblies and box builds for a wide range of industries. We provide value added engineering services and technical support including design, testing, prototyping and supply chain management to customers mainly in the aerospace and defense, medical, and industrial equipment markets. We maintain facilities in Bemidji, Blue Earth, Eden Prairie, Mankato, Merrifield, and Milaca, Minnesota; Monterrey, Mexico; and Suzhou, China. All of our facilities are certified to one or more of the ISO/AS standards, including 9001, AS9100 and 13485, with most having additional certifications based on the needs of the customers they serve.

### Results of Operations

The following table presents statements of operations data as percentages of total net sales for the periods indicated:

|  | Three Months Ended September 30, 2018 | 2017 | Nine Months Ended September 30, 2018 | 2017 |
| --- | ---: | ---: | ---: | ---: |
| Net Sales | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of Goods Sold | 88.5 | 87.6 | 87.9 | 88.5 |
| Gross Profit | 11.5 | 12.4 | 12.1 | 11.5 |
| Selling Expenses | 2.4 | 4.0 | 3.3 | 4.2 |
| General and Administrative Expenses | 6.8 | 7.4 | 7.3 | 7.1 |
| Gain on Sale of Property and Equipment | 0.0 | 0.0 | 0.0 | (0.4) |
| Income from Operations | 2.3 | 1.0 | 1.5 | 0.6 |
| Other Expenses | (0.7) | (0.6) | (0.7) | (0.7) |
| Income (Loss) Before Income Taxes | 1.6 | 0.4 | 0.8 | (0.1) |
| Income Tax Expense (Benefit) | 0.4 | 0.2 | 0.4 | (0.2) |
| Net Income | 1.2% | 0.2% | 0.4% | 0.1% |

### Net Sales

Net sales were $29.6 million in the third quarter of 2018, an increase of $1.2 million or 4.4% as compared to the third quarter of the prior year. Our 2018 third quarter amount includes $1.9 million of additional sales related to the change in the revenue recognition policy. Net sales results were varied by markets. The medical market increased by $1.5 million or 12.0% with medical component products accounting for 86% of the increase and medical devices the remaining 14%. The industrial market decreased by $0.4 million or 3.8% of sales in the third quarter of 2018 as compared to the same quarter of 2017. Net sales from the aerospace and defense markets increased by $0.2 million or 3.9% in the third quarter of 2018 as compared to the third quarter of 2017.

Net sales were $84.5 million in the nine months ended 2018, a decrease of $2.2 million as compared to the prior year comparable period. Our 2018 amounts include $4.2 million of additional sales related to the change in the revenue recognition policy. Net sales results were varied by markets. The medical market decreased by $4.2 million or 10.2% with medical component products accounting for 28% of the decrease and medical devices the remaining 72%. The industrial market decreased by $0.2 million or 0.7% of sales for the nine months ended 2018 as compared to the same period of 2017. Net sales from the aerospace and defense markets increased by $2.2 million or 19.4% for the nine months ended 2018 as compared to the same period of 2017.

Net sales by our major EMS industry markets for the three and nine months ended September 30, 2018 and 2017 were as follows (in thousands):

|  | Three Months Ended | Nine Months Ended |
| --- | ---: | ---: |
|  | **2018** **2017%** | **2018** **2017%** |
|  | **$$** **Change** | **$$** **Change** |
| Aerospace and Defense | 4,184 4,027 3.9 | 13,444 11,264 19.4 |
| Medical | 14,280 12,753 12.0 | 36,838 41,009 (10.2) |
| Industrial | 11,094 11,530 (3.8) | 34,261 34,489 (0.7) |
| Total Net Sales | 29,558 28,310 4.4 | 84,543 86,762 (2.6) |

Net sales by our major EMS industry markets for the three and nine months ended September 30, 2018, to the pro-forma amounts for the same period had the previous guidance been in effect (in thousands):

|  | Three Months Ended As Reported 2018 | Pro forma as if the previous accounting guidance was in effect | % Change | Nine Months Ended As Reported 2018 | Pro forma as if the previous accounting guidance was in effect | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Aerospace and Defense | $4,184 | $3,979 | 5.2 | $13,444 | $12,848 | 4.6 |
| Medical | 14,280 | 13,071 | 9.2 | 36,838 | 34,702 | 6.2 |
| Industrial | 11,094 | 10,615 | 4.5 | 34,261 | 32,773 | 4.5 |
| Total Net Sales | $29,558 | $27,665 | 6.8 | $84,543 | $80,323 | 5.3 |

Net sales by timing of transfer of goods and services for the three and nine months ended September 30, 2018 is as follows (in thousands):

|  | Three Months Ended September 30, 2018 Product/ Service Transferred Over Time | Product Transferred at Point in Time | Noncash Consideration | Total Net Sales by Market |
| --- | ---: | ---: | ---: | ---: |
| Aerospace and Defense | $3,931 | $50 | $203 | $4,184 |
| Medical | 13,461 | 151 | 668 | 14,280 |
| Industrial | 9,486 | 1,116 | 492 | 11,094 |
| Total net sales | $26,878 | $1,317 | $1,363 | $29,558 |

|  | Nine Months Ended September 30, 2018 Product/ Service Transferred Over Time | Product Transferred at Point in Time | Noncash Consideration | Total Net Sales by Market |
| --- | ---: | ---: | ---: | ---: |
| Aerospace and Defense | $12,675 | $170 | $599 | $13,444 |
| Medical | 34,513 | 720 | 1,605 | 36,838 |
| Industrial | 29,698 | 3,165 | 1,398 | 34,261 |
| Total net sales | $76,886 | $4,055 | $3,602 | $84,543 |

20

### Backlog

Our 90-day shipment backlog as of September 30, 2018 was $27.7 million, a 16.0% increase from the beginning of the quarter and a 36.6% increase as compared to the prior year. Backlog for our medical customers has increased 19.7% from the beginning of the quarter and increased 63.4% compared to the prior year. The aerospace and defense backlog remained flat from the beginning of the quarter and increased 22.2% from the prior year. Our industrial customers’ backlog increased 22.9% from the beginning of the quarter and increased 18.1% from the prior year. Our backlog consists of firm purchase orders we expect to ship in the next 90 days, with any remaining amounts to be transferred within 180 days.

90-day shipment backlog by our major EMS industry markets are as follows (in thousands):

|  | Shipment Backlog as of the Quarter Ended September 30, 2018 | June 30, 2018 | September 30, 2017 |
| --- | ---: | ---: | ---: |
| Aerospace and Defense | $5,530 | $5,568 | $4,524 |
| Medical | 12,902 | 10,776 | 7,897 |
| Industrial | 9,279 | 7,552 | 7,860 |
| Total Backlog | $27,711 | $23,896 | $20,281 |

Our 90-day backlog varies due to order size, manufacturing delays, contract terms and conditions and timing from customer delivery schedules and releases. These variables cause inconsistencies in comparing the backlog from one period to the next.

### Gross Profit

Gross profit as a percent of net sales for the three months ended September 30, 2018 and 2017, was 11.5% and 12.4%, respectively. The decline in gross profit in the third quarter of 2018 was driven by customer and product mix. In addition, we recognized revenue of $1.4 million related to the noncash consideration recorded at zero margin as a result of implementing revenue recognition.

Gross profit as a percentage of sales for the nine months ended September 30, 2018 and 2017 was 12.1% and 11.5% respectively. The year to date improvement in gross profit was driven by customer and product mix, operational efficiencies and cost improvements as we adjusted to current revenue levels. In addition, we recognized revenue of $3.6 million related to the noncash consideration recorded at zero margin as a result of implementing revenue recognition.

### Selling Expense

Selling expenses for the three months ended September 30, 2018 and 2017 was $0.7 million or 2.4% of sales and $1.1 million or 4.0% of sales, respectively. Selling expense for the nine months ended September 30, 2018 and 2017 was $2.8 million or 3.3% of sales and $3.7 million or 4.2% of sales, respectively. The decrease in both the three and nine month periods is due to timing of events and volume dependent expenses.

### General and Administrative Expense

General and administrative expenses for the three months ended September 30, 2018 and 2017, were $2.0 million or 6.8% of sales and $2.1 million or 7.4% of sales, respectively. General and administrative expenses for the nine months ended September 30, 2018 and 2017, were $6.2 million or 7.3% of sales and $6.2 million or 7.1% of sales, respectively. The year over year comparison is consistent due to our adjustment of spending based on customer demands.

### Gain from Sale of Property and Equipment

There was no sales of property and equipment recorded for the three and nine months ended September 30, 2018. Net gain from sale of property and equipment for the nine months ended September 30, 2017 was $0.4 million from the sale of the Augusta building and building improvements (see Note 7).

### Income from Operations

Third quarter 2018 income from operations was $0.6 million compared to income of $0.3 million for the third quarter in 2017. The increase in income from operations for the period was due to operational efficiencies and spending control.

Income from operations for the first nine months in 2018 was $1.3 million as compared to $0.5 million for the same comparable period in 2017. The increase in income from operations for the period was due to the gross profit improvement and cost containment activities.

### Income Taxes

On a quarterly basis, we estimate what our effective tax rate will be for the full fiscal year and record a quarterly income tax provision based on the anticipated rate. As the year progresses, we refine our estimate based on the facts and circumstances, including discrete events, by each tax jurisdiction. Our effective tax rate for the three and nine months ended September 30, 2018 was 24% and 49%, respectively. Our effective tax rate for the three and nine months ended September 30, 2017 was 61.5% and 110.2%, respectively. Our effective tax rate for the year ended December 31, 2018 is expected to be 51% compared to (18%) for the year ended December 31, 2017. The increase is due mainly to the effects of the tax reform changes that were enacted on December 22, 2017, and the increase in the effective tax rate expected in China.

### Net Income

Net income for the three months ended September 30, 2018 was $0.4 million or $0.14 per basic and diluted common share, compared to a net income for the three months September 30, 2017 of $43 thousand or $0.02 per basic and diluted common share. Net income for the nine months ended September 30, 2018 was $0.4 million or $0.13 per basic and diluted common share compared to net income for the nine months ended September 30, 2017 of $13 thousand with no earnings per basic and diluted common share.

### Liquidity and Capital Resources

Net cash provided by operating activities for the nine months ended September 30, 2018 was $2.6 million. The noncash addback of depreciation and amortization, along with an increase in accounts payable, has positively impacted cash flows, offset by an increase in accounts receivable and inventories.

Net cash used in investing activities of $1.0 million for the nine months ended September 30, 2018, was the result of property and equipment purchases to support the business.

We have satisfied our liquidity needs over the past several years with cash flows generated from operations and a bank operating line of credit. We have a credit agreement with Bank of America (BofA) which was entered into on June 15, 2017 and amended on December 29, 2017 and provides for a line of credit arrangement of $16.0 million that expires on June 15, 2022. The credit arrangement also has a $5.0 million real estate term note outstanding with a maturity date of June 15, 2022.

Both the line of credit and real estate term notes are subject to fluctuations in the LIBOR rates. The line of credit and real estate term notes with BofA contain certain covenants which, among other things, require us to adhere to regular reporting requirements, abide by annual shareholder dividend limitations, maintain certain financial performance, and limit the amount of annual capital expenditures. The availability under our line is subject to borrowing base requirements, and advances are at the discretion of the lender. The line of credit is secured by substantially all of our assets.

On September 30, 2018, we had outstanding advances of $8.1 million under the line of credit and unused availability of $4.8 million supported by our borrowing base compared to December 31, 2017 outstanding advances of $8.5 million and unused availability of $4.2 million. We believe our financing arrangements and cash flows to be provided by operations will be sufficient to satisfy our future working capital needs. Our working capital was $20.2 million and $19.7 million as of September 30, 2018 and December 31, 2017, respectively.

The Bank of America credit agreement as amended provides for, among other things, a fixed charge coverage ratio of not less than (i) 1.0 to 1.0 for each period of four fiscal quarters, commencing with the period of four fiscal quarters ending December 31, 2018. In addition, the agreement requires that the Company comply with certain minimum levels of cumulative EBITDA for measurement periods during fiscal 2018, including cumulative EBITDA of $2.0 million for the twelve months ending December 31, 2018.

Cash conversion cycle:

|  | Three Months Ended September 30, 2018 | September 30, 2017 | Nine Months Ended September 30, 2018 | September 30, 2017 |
| --- | ---: | ---: | ---: | ---: |
| Days in trade accounts receivable | 58 | 55 | 58 | 53 |
| Days in inventory | 54 | 79 | 52 | 77 |
| Days in accounts payable | (54) | (52) | (49) | (52) |
| Cash conversion cycle | 58 | 82 | 61 | 78 |
| Cash conversion cycle without adoption of ASU 2014-09 | 57 | 82 | 61 | 78 |

We calculate days in accounts receivable as accounts receivable for the respective quarter divided by annualized sales for the respective quarter by day. We calculate days in inventory and accounts payable as each balance sheet line item for the respective quarter divided by annualized cost of sales for the respective quarter by day. We calculate cash conversion cycle as the sum of days in receivable and inventory less days in accounts payable. Items which may cause the cash conversion cycle in a particular period to differ include, but are not limited to, changes in business mix, timing of cash collections and cash payments, changes in payment terms and the timing of revenue recognition and inventory purchases within the period. Days in inventory for the three months and nine months ended September 30, 2018 decreased as compared to the three and nine months ended September 30, 2017 primarily related to the adoption of ASU 2014-09 and the recognition of revenue over time rather than upon shipment of inventory. The increase in days in accounts receivable related to increased payment terms requested by our customers and a decrease in days in accounts payable for the quarter, as a result of the timing of payments.

### Off-Balance Sheet Arrangements

We have not engaged in any off-balance sheet activities as defined in Item 303(a)(4) of Regulation S-K.

### Critical Accounting Policies and Estimates

Our significant accounting policies and estimates are summarized in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2017. There has been significant changes to our critical accounting policies since December 31, 2017, related to the implementation of the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09,

“Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”), refer to Note 1 and Note 3. The adoption of the new revenue standard had a significant impact on our results of operations, cash flows, and financial position. Some of our accounting policies require us to exercise significant judgment in selecting the appropriate assumptions for calculating financial estimates. Such judgments are subject to an inherent degree of uncertainty. These judgments are based on our historical experience, known trends in our industry, terms of existing contracts and other information from outside sources, as appropriate. Actual results could differ from these estimates.

### Forward-Looking Statements

Those statements in the foregoing report that are not historical facts are forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements generally will be accompanied by words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “possible,” “potential,” “predict,” “project,” or other similar words that convey the uncertainty of future events or outcomes. Although we believe these forward-looking statements are reasonable, they are based upon a number of assumptions concerning future conditions, any or all of which may ultimately prove to be inaccurate. Forward-looking statements involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from the forward-looking statements include, without limitation:

- Volatility in the marketplace which may affect market supply and demand for our products or currency exchange rates;
- Increased competition from within the EMS industry or the decision of OEMs to cease or limit outsourcing;
- Changes in the reliability and efficiency of operating facilities or those of third parties;
- Risks related to availability of labor;
- Increase in certain raw material costs such as copper and oil;
- Commodity and energy cost instability;
- Risks related to FDA noncompliance;
- Loss of a major customer;
- Increased or unanticipated costs related to compliance with securities and environmental regulation;
- General economic, financial and business conditions that could affect our financial condition and results of operations; and
- Disruption of global or local information management systems due to natural disaster or cyber-security incident.

The factors identified above are believed to be important factors (but not necessarily all of the important factors) that could cause actual results to differ materially from those expressed in any forward-looking statement made by us. Discussion of these factors is also incorporated in Part I, Item 1A, “Risk Factors,” and should be considered an integral part of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Unpredictable or unknown factors not discussed herein could also have material adverse effects on forward-looking statements. All forward-looking statements included in this Form 10-Q are expressly qualified in their entirety by the forgoing cautionary statements. We undertake no obligations to update publicly any forward-looking statement (or its associated cautionary language) whether as a result of new information or future events.

Please refer to forward-looking statements and risks as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017.

## Controls and procedures

As filed, 1,430 characters.

### Evaluation of Disclosure Controls and Procedures

In accordance with Rule 13a-15(b) of the Securities Exchange Act of 1934 (the “Exchange Act”), as of the end of the period covered by this Quarterly Report on Form 10-Q, our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act). These controls and procedures are designed to ensure that information required to be disclosed in the Company’s Exchange Act reports is (1) recorded, processed, summarized and reported in a timely manner, and (2) accumulated and communicated to management, including the Company’s Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon their evaluation of these disclosure controls and procedures as of the date of the evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedures were effective.

### Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 1,871 characters.

We are affected by the risks specific to us as well as factors that affect all businesses operating in a global market. The significant factors known to us that could materially adversely affect our business, financial condition or operating results or could cause our actual results to differ materially from our expectations are described in our annual report on Form 10-K for the fiscal year ended under the heading “Part I — Item 1A.Risk Factors.” Other than as noted below, there have been no material changes in the risk factors from those disclosed in the Annual Report on Form 10-K for the year ended December 31, 2017.

***We may experience difficulties implementing our new global enterprise resource planning system.***

We are engaged in an implementation of a new global enterprise resource planning system (ERP). The ERP is designed to efficiently maintain our books and records and provide information important to the operation of our business to our management team. The ERP implementation has and will continue to require significant investment of human and financial resources. In implementing the ERP, we may experience significant delays, increased costs and other difficulties. Any significant disruption or deficiency in the design and implementation of the ERP could adversely affect our ability to process orders, ship product, send invoices and track payments, fulfill contractual obligations or otherwise operate our business. While we have invested significant resources in planning, project management and training, additional and significant implementation issues may arise. In addition, our efforts to adjust and centralize various business processes and functions within our organization in connection with our ERP implementation may disrupt our operations and negatively impact our business, results of operations and financial condition.

Filed Nov 14, 2018.
Source: SEC EDGAR, the filing index for accession 0001104659-18-068455. Last ingested by Listed: Nov 12, 2026, 19:20 ET. No prices; not investment advice.
